Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Aandeel OXURION BRU:OXUR.BL, BE0003846632

  • 1,890 17 sep 2021 17:29
  • +0,064 (+3,50%) Dagrange 1,824 - 1,890
  • 21.900 Gem. (3M) 33,9K

Oxurion in 2019

180 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste | Omlaag ↓
  1. jus1711 4 februari 2019 16:18
    Leuven, Belgium, 4 February 2019 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview and clinical update at the 2019 BIO CEO & Investor Conference. The presentation will take place at 11:15 a.m. EST on Tuesday, Feb. 12, 2019 in the Herald/Soho room at the New York Marriott Marquis.

    Oxurion’s management team will also hold one-on-one meetings with institutional investors and analysts Feb. 11-14 in New York.

    Patrik De Haes, MD, CEO of Oxurion NV, commented: “It is a particularly pivotal time at Oxurion given the progress of our 4 clinical programs, each slated to read out in the second half of 2019. We look forward to providing a company update at the BIO CEO & Investor Conference as we continue to advance our pipeline of disease-modifying therapies in the clinic and remain confident in the potential of each therapy to preserve vision in patients with diabetic eye disease.”
  2. relpinda 5 maart 2019 20:49
    UPDATE
    Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
    Nieuws via RSS voor Oxurion (ex ThromboGenics)
    28 februari 2019 08:01
    Leuven, Belgium, 28 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it will present at the 9th European Society of Retina Specialists (EURETINA) Winter Meeting, which is being held March 1-2, 2019 in Prague, Czech Republic at the Clarion Congress Hotel.

    The poster "Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model" shows results of the inhibitory effect of repeated administration of THR-149, Oxurion's novel plasma kallikrein (PKal) inhibitor, on retinal vascular leakage and inflammation in the diabetic rat STZ model, compared to vehicle-treated eyes. These positive results highlight THR-149's potential as a treatment option for diabetic macular edema (DME). Oxurion is currently conducting a Phase 1 clinical study evaluating the safety of THR-149 in DME patients with initial data read out expected towards the end of 2019.

    Patrik De Haes, M.D., CEO of Oxurion nv, commented: "We look forward to presenting the results of our preclinical research with THR-149 in the field of DME at the EURETINA Winter Meeting. The results of the study demonstrate the potential therapeutic benefits of THR-149, our plasma kallikrein inhibitor, on the key disease hallmarks of DME including retinal vascular leakage and inflammation. These results further substantiate the disease-modifying capabilities of this novel drug candidate and its potential to address the clear unmet need for improved treatment options for diabetic eye disease."

    END

    For further information please contact:

    Oxurion NV
    Wouter Piepers,
    Global Head of Corp Coms & Investor relations
    +32 16 75 13 10 / +32 478 33 56 32
    wouter.piepers@oxurion.com

    LZA
180 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

OXURION Meer »

Koers 1,890   Verschil +0,06 (+3,50%)
Laag 1,824   Volume 21.900
Hoog 1,890   Gem. Volume 33.908
17 sep 2021 17:29
label premium

Positieve data Oxurion stemmen optimistisch

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links